Alper Ozturk

Alper Ozturk

Auto-generated profile, based on publicly available information

Alper Ozturk

Biruni Univ, Fac Med, Dept Gen Surg, Istanbul, Turkiye

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021
Verified
Journal Article
Closed access
AOAlper Ozturk
Alper Ozturk
SISerkan Ilgun
Serkan Ilgun
MUMuhammed Ucuncu
Muhammed Ucuncu
FGFiruz Gachayev
Firuz Gachayev
COCetin Ordu
Cetin Ordu
VOVahit Ozmen
Vahit Ozmen

24 June 2020 in European Journal of Breast Health
Verified
Journal Article
Closed access
FCFiliz Celebi
Filiz Celebi
Çetin OrduÇetin Ordu
Çetin Ordu
AIAhmet Serkan Ilgun
Ahmet Serkan Ilgun
AOAlper Ozturk
Alper Ozturk
ZIZeynep Erdogan Iyigun
Zeynep Erdogan Iyigun
VÖVahit Özmen
Vahit Özmen
AMH,ovarian reserve,breast cancer,chemotherapy

19 October 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
ÇÜÇağlar Ünal
Çağlar Ünal
Çetin OrduÇetin Ordu
Çetin Ordu
TÖTolga Özmen
Tolga Özmen
AIAhmet Serkan İlgun
Ahmet Serkan İlgun
FÇFiliz Çelebi
Filiz Çelebi
VÖVahit Özmen
Vahit Özmen
Estradiol (E2), a follicle-stimulating hormone (FSH), AMH, and inhibin B levels, along with AFC and MOV, are used to determine ovarian reserve in pre-menopausal women. Studies have shown that AMH levels are more sensitive than those of E2, FSH, and inhibin B and that AFC and MOV can be used to evaluate ovarian reserve. AMH, AFC, and MOV measurements were performed before and after adjuvant SC in 3-month periods for one year. Patients were classified as experiencing chemotherapy-induced amenorrhea (CIA) if they did not have menstrual cycles for a period of six months or longer following the conclusion of their chemotherapy treatment. We aimed to evaluate the factors affecting chemotherapy-induced amenorrhea in breast cancer patients treated with adjuvant chemotherapy and the performance of baseline measurements of AMH, AFC, and MOV to predict chemotherapy-induced amenorrhea. The effects of different chemotherapy regimens on the AMH level, AFC, and MOV in CIA patients were investigated. Seventy-one patients were eligible for this study, and the median age was 38 years (range: 23–45). The median follow-up was 37 months (range: 20–51), and CIA developed in 62% of the patients. The AMH level and AFC were significantly decreased one year after SC (p < 0.0001), whereas MOV was not (p = 0.507). AMH levels before chemotherapy (median: 1.520 vs. 0.755, p = 0.001) and at the end of the first year (median: 0.073 vs. 0.010, p = 0.030) and pre-treatment AFC (median: 12 vs. 4.50, p = 0.026) were lower in patients with CIA compared to those without CIA. The AMH levels before SC were the most valuable and earliest factor for predicting CIA development. In addition, there was no difference between the chemotherapy regimens (including or not including taxane) in terms of CIA development.

29 June 2018 in European Journal of Breast Health
Verified
Journal Article
Closed access
Çetin OrduÇetin Ordu
Çetin Ordu
KPKezban Nur Pilanci
Kezban Nur Pilanci
Gül AlçoGül Alço
Gül Alço
FEFiliz Elbuken
Filiz Elbuken
UKUlkuhan Iner Koksal
Ulkuhan Iner Koksal
VÖVahit Özmen
Vahit Özmen
Objective: In this retrospective study, chemotherapy induced amenorrhea in patients with early stage breast cancer and its effects on survival were investigated. Materials and Methods: Two hundred fifty-two patients received adjuvant chemotherapy without ovarian suppression treatment (OST) from 600 premenopausal patients were included in the study. Patients were divided into two groups; with amenorrhea and without, and compared with clinicopathologic features and survival. SPSS version 17 was used. Results: Chemotherapy-induced amenorrhea (CIA) was observed in 145 (57.5%) of 252 patients who received no OST during follow-up. The 5-year OS rate of patients with CIA was significantly higher than patients without CIA (p=0.042, 95.9% vs. 89.7% vs. 158.88 vs. 135.33 months, respectively). In the subgroup analysis, the OS in patients with hormone receptor (+) was significantly higher than in those receptor (-) in patients with CIA (p=0.011, 97.5% vs. 90.9% vs. 162.13 vs. 126.16 months, respectively). The OS was significantly longer in the luminal A molecular subtype than in those with luminal B molecular subtype, in patients with CIA, but the difference was not significant in patients without CIA (p=0.027 vs. p=0.074, respectively).** Conclusion: As a conclusion; survival advantage of the chemotherapy induced amenorrhea more pronounced with hormone receptor positivity, lymph node involvement, and advanced disease over patients who do not develop amenorrhea. This advantage of amenorrhea development further prolongs survival compared with luminal B in the luminal A molecular subtype.

2 January 2025 in European Journal of Breast Health
Verified
Journal Article
Open access
ZİZeynep Erdoğan İyigün
Zeynep Erdoğan İyigün
TOTolga Ozmen
Tolga Ozmen
SISerkan İlGün
Serkan İlGün
CNCansu Nakipoğlu
Cansu Nakipoğlu
EÖEnver Özkurt
Enver Özkurt
GSGürsel Soybir
Gürsel Soybir
Undefined - European Journal of Breast Health

14 August 2022 in Cureus
Verified
Journal Article
Open access
AOAlper Ozturk
Alper Ozturk
YCYusuf Celik
Yusuf Celik
Background: Our research aimed to see how sleeve gastrectomy (SG) affects weight loss and comorbidities in patients with a body mass index (BMI) ≥ 50 kg/m². Materials and methods: Prospectively kept data of patients with a BMI ≥50 kg/m² who underwent SG between February 2016 and February 2020 were evaluated. Results: A total of 138 patients with a BMI ≥ 50 kg/m² were operated on. The average BMI was 56.36±7.661, the average age was 37.41±12.33. Forty-eight patients underwent concomitant cholecystectomy and/or hiatal hernia repair (HHR). The percentage of excess weight loss (EWL%) of patients at the 3rd, 6th, 12th, 18th, and 24th months were 36%, 54%, 67%, 72%, and 74%, respectively. Mean BMI values of the 0th, 3rd, 6th, 12th, 18th, and 24th months were 56, 45, 39, 35, 33, and 33, respectively. 0th, 3rd, 6th, 12th, 18th, and 24th months were significantly different for EWL%, total weight loss (TWL%), and BMI variables (p<0.001), but EWL% (p=0.527), TWL% (p=0.396) and BMI (p=0,657) were not found significantly different between the 18th and 24th months. When EWL% ≥ 50 was accepted, the success rate was 93% (n=93) and 92% (n=50) at the 18th and 24th months, respectively. While there was 82% remission in type 2 diabetes mellitus (DM) and 90% in hypertension (HT), the remission rate in patients with obstructive sleep apnea syndrome (OSAS) and gastroesophageal reflux disease (GERD) undergoing HHR was 100%. Conclusions: In patients with a BMI ≥ 50 kg/m², SG seems to be an effective and safe therapy option as the first line for weight loss and treatment of comorbid diseases. Further long-term studies are needed to confirm these results.